相关实验视频

Updated: May 2, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

通过结合深度学习,分子建模和生物评估,发现新型潜在的11β-HSD1抑制剂

Xiaodie Chen^1,2, Liang Zou^1,2, Lu Zhang^1,2

¹School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, 400054, China.

Molecular diversity

|May 21, 2025

概括

研究人员使用深度学习开发了一种用于11β-Hydroxysteroid脱酶1型 (11β-HSD1) 抑制剂的新型生成模型. 这种方法成功地确定了代谢障碍的潜在候选药物,包括一个先前已知的抑制剂.

科学领域:

药用化学医学化学
计算化学计算化学
药物发现药物发现药物发现

背景情况:

11β-Hydroxysteroid脱酶1型 (11β-HSD1) 是一种关键酶,与胰岛素抵抗和肥胖等代谢疾病有关.
针对11β-HSD1为这些疾病提供了一个有前途的治疗策略.

研究的目的:

开发一种新的分子生成模型,用于识别潜在的11β-HSD1抑制剂.
为了利用深度学习和转移学习,实现高效的药物发现.

主要方法:

一个基于Gated Recurrent Unit (GRU) 的神经网络被训练在一个大数据集上的药物样分子上.
使用已知的11β-HSD1抑制剂应用转移学习.
在过 (利宾斯基规则,ADME/T) 和分子模拟 (对接,动态) 被使用.
对所选化合物进行了体外验证.

主要成果:

该GRU模型成功生成了类似药物的分子和潜在的11β-HSD1抑制剂.
通过多步检查确定了五种潜在的化合物.
化合物02被证实是已知的11β-HSD1抑制剂.
化合物02在体外表现出抑制活性,尽管效果不如对照组那么强.

结论:

这项研究证明了深度学习和转移学习在发现新型11β-HSD1抑制剂方面的有效性.
开发的方法提供了针对代谢障碍的药物开发的新方法.
对已识别的化合物进行进一步优化是有必要的.

关键词:

11β-基类固醇脱酶1型活动评估活动评估.有门的经常性单位.分子模拟分子模拟转移学习转移学习虚拟选是一个虚拟的选.

更多相关视频

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...